US-based MediBeacon Inc. has reached a $30 million deal giving China’s Huadong Medicine Co. Ltd. exclusive rights to its portfolio in China, Hong Kong, Macau and Taiwan, according to a statement.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
